ProPhase Labs, Inc. Gain (Loss) on Termination of Lease
ProPhase Labs, Inc. (PRPH) reported Gain (Loss) on Termination of Lease of -$1.36 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-06-01.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnTerminationOfLease · last filed 2026-08-19
- ProPhase Labs, Inc. gain (loss) on termination of lease for the quarter ending 2025-09-30 was -$1.40M.
- ProPhase Labs, Inc. gain (loss) on termination of lease for the quarter ending 2025-06-30 was -$1.40M.
- ProPhase Labs, Inc. gain (loss) on termination of lease for fiscal 2025 was -$1.36M.
- ProPhase Labs, Inc. gain (loss) on termination of lease for fiscal 2024 was $0.00.
| Period end | Gain (Loss) on Termination of Lease 1 month | Gain (Loss) on Termination of Lease 3 month | Gain (Loss) on Termination of Lease 6 month | Gain (Loss) on Termination of Lease 9 month | Gain (Loss) on Termination of Lease 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | -$1.36M 10-K · filed 2026-06-01 | ||||
| 2025-09-30 | -$1.40M 10-Q · filed 2025-11-19 | -$1.36M 10-Q · filed 2025-11-19 | |||
| 2025-06-30 | -$1.40M 10-K · filed 2026-06-01 | -$1.40M 10-Q · filed 2025-08-13 | -$1.36M 10-Q · filed 2026-08-19 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-06-01 | ||||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-19 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |